イワモト　タカユキ   Takayuki Iwamoto   岩本　高行    所属   川崎医科大学  医学部 臨床医学　乳腺甲状腺外科学    職種   講師
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Inflammatory breast cancer: what we know and what we need to learn.
掲載誌名	正式名：The oncologist 略　 称：Oncologist ISSNコード：1549490X/10837159
掲載区分	国外
巻・号・頁	17(7),pp.891-9
著者・共著者	Hideko Yamauchi, Wendy A Woodward, Vicente Valero, Ricardo H Alvarez, Anthony Lucci, Thomas A Buchholz, Takayuki Iwamoto, Savitri Krishnamurthy, Wei Yang, James M Reuben, Gabriel N Hortobágyi, Naoto T Ueno
発行年月	2012
概要	PURPOSE:We review the current status of multidisciplinary care for patients with inflammatory breast cancer (IBC) and discuss what further research is needed to advance the care of patients with this disease.DESIGN:We performed a comprehensive review of the English-language literature on IBC through computerized literature searches.RESULTS:Significant advances in imaging, including digital mammography, high-resolution ultrasonography with Doppler capabilities, magnetic resonance imaging, and positron emission tomography-computed tomography, have improved the diagnosis and staging of IBC. There are currently no established molecular criteria for distinguishing IBC from noninflammatory breast cancer. Such criteria would be helpful for the diagnosis and development of novel targeted therapies. Combinations of neoadjuvant systemic chemotherapy, surgery, and radiation therapy have led to an improved prognosis; however, the overall 5-year survival rate for patients with IBC remains very low (∼30%). Sentinel lymph node biopsy and skin-sparing mastectomy are not recommended for patients with IBC.CONCLUSION:Optimal management of IBC requires close coordination among medical, surgical, and radiation oncologists, as well as radiologists and pathologists. There is a need to identify molecular changes that define the pathogenesis of IBC to enable eradication of IBC with the use of IBC-specific targeted therapies.
DOI	10.1634/theoncologist.2012-0039
PMID	22584436